Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study

被引:0
|
作者
Puskulluoglu, Miroslawa [1 ]
Pieniazek, Malgorzata [2 ,3 ]
Las-Jankowska, Manuela [4 ,5 ]
Streb, Joanna [6 ]
Ziobro, Marek [1 ]
Pacholczak-Madej, Renata [7 ,8 ,9 ]
Kilian-Van Miegem, Paulina [10 ]
Rudzinska, Agnieszka [1 ]
Grela-Wojewoda, Aleksandra [1 ]
Lacko, Aleksandra [2 ,3 ]
Jarzab, Michal [11 ]
Polakiewicz-Gilowska, Anna [11 ]
机构
[1] Mar Sklodowska Curie Natl Res Inst Oncol, Krakow Branch, Dept Clin Oncol, Krakow, Poland
[2] Wroclaw Med Univ, Dept Oncol, Plac Hirszfelda 12, PL-53413 Wroclaw, Poland
[3] Lower Silesian Comprehens Canc Ctr, Plac Hirszfelda 12, PL-53413 Wroclaw, Poland
[4] Nicolaus Copernicus Univ Torun, Oncol Ctr, Ludw Rydygier Coll Medicum Bydgoszcz, Surg Oncol, PL-85067 Bydgoszcz, Poland
[5] Prof Franciszek Lukaszczyk Mem Hosp, Oncol Ctr, Dept Clin Oncol, PL-85796 Bydgoszcz, Poland
[6] Jagiellonian Univ, Med Coll, Dept Oncol, PL-31008 Krakow, Poland
[7] Jagiellonian Univ, Med Coll, Dept Anat, Swietej Anny 12, PL-31008 Krakow, Poland
[8] Mar Sklodowska Curie Natl Res Inst Oncol, Krakow Branch, Dept Gynecol Oncol, Garncarska St 11, PL-31115 Krakow, Poland
[9] Dist Hosp, Dept Chemotherapy, Szpitalna St 22, PL-34200 Sucha Beskidzka, Poland
[10] Oncol Ctr Prof F Lukaszczyk Bydgoszcz, Chemotherapy Outpatient Clin, PL-85796 Bydgoszcz, Poland
[11] Mar Sklodowska Curie Natl Res Inst Oncol, Gliwice Branch, Breast Canc Unit, PL-44102 Gliwice, Poland
关键词
Triple-negative breast cancer; Metastases; Sacituzumab govitecan; Real-world study; Poland;
D O I
10.1007/s40487-024-00307-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionSacituzumab govitecan (SG) is approved for patients with previously treated metastatic or locally advanced triple-negative breast cancer (TNBC), as per the ASCENT trial results. Real-world studies (RWSs) cover more diverse patients than clinical trials, offering crucial data for healthcare policies. This study aimed to investigate the safety and efficacy of SG in real-world Polish patients with previously treated metastatic TNBC.MethodsIn this ambispective multicenter cohort study, we collected demographic and clinical data. Premedication, adjustments in SG dosage, and treatment regimen adhered to the product's characteristics.ResultsWe included 79 female patients. The median age at SG initiation was 53 years; 32% of patients were initially diagnosed with a non-TNBC subtype. The median number of previous palliative lines was 2. Seven patients presented with brain metastases. The median overall survival was 10.3 months, and the median progression-free survival (PFS) was 4.4 months. The overall response rate was 35%, with a median time to response of 2 months. SG was discontinued by 70% of patients, primarily due to disease progression (95%). Treatment delays due to adverse events (AEs) occurred in 67% and dose reductions in 25% of patients, with neutropenia being the most common. Grade >= 2 AEs included neutropenia (43%), anemia (10.1%), and diarrhea (4%). A longer interval between breast cancer diagnosis and SG initiation or between metastasis diagnosis and SG initiation correlated with improved PFS, likely reflecting the disease's biological aggressiveness rather than treatment efficacy.ConclusionIn this RWS, SG demonstrated effectiveness and safety in patients with previously treated metastatic TNBC, consistent with ASCENT trial outcomes. Further research is needed to explore the efficacy of SG in different patient populations and healthcare systems.
引用
收藏
页码:787 / 801
页数:15
相关论文
共 50 条
  • [31] Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
    Hurvitz, Sara A.
    Bardia, Aditya
    Punie, Kevin
    Kalinsky, Kevin
    Carey, Lisa A.
    Rugo, Hope S.
    Dieras, Veronique
    Phan, See
    Delaney, Rosemary
    Zhu, Yanni
    Tolaney, Sara M.
    NPJ BREAST CANCER, 2024, 10 (01)
  • [33] Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China
    Chen, Yimeng
    Guan, Yin
    Wang, Jiayu
    Ma, Fei
    Luo, Yang
    Chen, Shanshan
    Zhang, Pin
    Li, Qing
    Cai, Ruigang
    Li, Qiao
    Mo, Hongnan
    Lan, Bo
    Chen, Xuelian
    Zhao, Weihong
    Xu, Binghe
    Fan, Ying
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (12) : 3490 - 3499
  • [34] Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
    Hurvitz, Sara A.
    Tolaney, Sara M.
    Punie, Kevin
    Loirat, Delphine
    Oliveira, Mafalda
    Kalinsky, Kevin
    Zelnak, Amelia
    Aftimos, Philippe
    Dalenc, Florence
    Sardesai, Sagar
    Hamiltion, Erika
    Sharma, Priyanka
    Recalde, Sabela
    Gil, Eva Ciruelos
    Traina, Tiffany
    O'Shaughnessy, Joyce
    Cortes, Javier
    Tsai, Michaela
    Vahdat, Linda
    Dieras, Veronique
    Carey, Lisa
    Rugo, Hope S.
    Goldenberg, David M.
    Hong, Quan
    Olivo, Martin
    Itri, Loretta M.
    Bardia, Aditya
    CANCER RESEARCH, 2021, 81 (04)
  • [35] Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
    Bardia, A.
    Tolaney, S. M.
    Punie, K.
    Loirat, D.
    Oliveira, M.
    Kalinsky, K.
    Zelnak, A.
    Aftimos, P.
    Dalenc, F.
    Sardesai, S.
    Hamilton, E.
    Sharma, P.
    Recalde, S.
    Gil, E. C.
    Traina, T.
    O'Shaughnessy, J.
    Cortes, J.
    Tsai, M.
    Vahdat, L.
    Dieras, V
    Carey, L. A.
    Rugo, H. S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M.
    Itri, L. M.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 (09) : 1148 - 1156
  • [36] Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases
    Grinda, Thomas
    Morganti, Stefania
    Hsu, Liangge
    Yoo, Tae-Kyung
    Kusmick, Ross J.
    Aizer, Ayal A.
    Giordano, Antonio
    Leone, Jose P.
    Hughes, Melissa
    Tolaney, Sara M.
    Lin, Nancy U.
    Sammons, Sarah L.
    NPJ BREAST CANCER, 2025, 11 (01)
  • [37] Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer
    Skinner, Karen E.
    Haiderali, Amin
    Huang, Min
    Schwartzberg, Lee S.
    FUTURE ONCOLOGY, 2021, 17 (08) : 931 - 942
  • [38] FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer
    Wahby, Sakar
    Fashoyin-Aje, Lola
    Osgood, Christy L.
    Cheng, Joyce
    Fiero, Mallorie H.
    Zhang, Lijun
    Tang, Shenghui
    Hamed, Salaheldin S.
    Song, Pengfei
    Charlab, Rosane
    Dorff, Sarah E.
    Ricks, Tiffany K.
    Barnett-Ringgold, Kimberly
    Dinin, Jeannette
    Goldberg, Kirsten B.
    Theoret, Marc R.
    Pazdur, Richard
    Amiri-Kordestani, Laleh
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1850 - 1854
  • [39] Sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments
    Xu, B.
    Ma, F.
    Wang, S.
    Tong, Z.
    Li, W.
    Wu, X.
    Wang, X.
    Sun, T.
    Pan, Y.
    Yao, H.
    Wang, X.
    Luo, T.
    Yang, J.
    Zeng, X.
    Zhao, W.
    Cong, X. J.
    Chen, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S650 - S650
  • [40] Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer
    Seligson, John M.
    Patron, Alexandra M.
    Berger, Michael J.
    Harvey, R. Donald
    Seligson, Nathan D.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (07) : 921 - 931